Pressure BioSciences' Schumacher upbeat on market potential for its life science tools

Pressure BioSciences Inc (OTCMKTS:PBIO) chief Richard T. Schumacher told a recent interview in New York that he believes the market opportunity for the group's tools, which prepare samples, runs into multi billions of US dollars.

"We think there's at least 500,000 researchers and at least 80,000 labs that can use of our system," he told the SNNLive video interview.

WATCH IT HERE...

"Right now we are in about 165 labs of the 80,000. We are a small company. We've had one salesperson for the last nine years. We've had minimal money to develop things. We had one instrument that was run by a microprocessor. Things have really changed for us in the last year."

Schumacher explained how the group now had six salespeople, with four new instruments that are ready to come out on top of the one it already had.

"We now have a brand new instrument that is computer driven, not run by a microprocessor, has tremendous software."

Earlier this month, Pressure BioSciences said it was very excited about the potential for its ultra shear technology (UST), for which it has been issued its first two patents in China.

The technology could be used in a range of industrial applications, including extending the shelf life of some food products, the firm said.

Last week, Pressure said it was to collaborate with Phasex Corporation to combine its ultra shear technology with the latter's processing methods to develop water-soluble nanoemulsions.

These (nanoemulsions) are mixtures of two or more liquids, which could be used in various products, including medical, pharmaceuticals, and nutraceuticals, and the companies hope to create a CBD-enriched plant oil.

Pressure Biosciences's Schumacher has also conducted an interview with NetworkNewsWire (NNW), a financial news and publishing company.

WATCH IT HERE.

"We supply instruments and consumables to life science laboratories all over the world," says Schumacher.

"These are the laboratories that are aggressively looking for the next billion-dollar drug, the next cure, the next preventive strategy, the next vaccine."
Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.